OR51E2 and prostate carcinoma: Interestingly, identification of biologically relevant ligands for OR51E2, which was also found to be a key marker for prostate cancer, revealed that out of the 2500 virtually screened and subsequently 55 experimentally validated compounds [16], several endogenous compounds could activate OR51E2.